To update the Partin Tables for prediction of pathological stage in the contemporary setting and examine trends in patients treated with radical prostatectomy (RP) over the past three decades.
Introduction
The ability to accurately predict outcomes after radical prostatectomy (RP) using preoperative data remains critical in the counselling and decision-making process of men with prostate cancer. First introduced in 1993, the 'Partin Tables' use clinical stage, serum PSA level, and biopsy Gleason score to predict pathological stage at RP [1] . This straightforward approach has subsequently been validated in several populations throughout the USA and abroad [2] [3] [4] [5] [6] [7] .
The original Partin Tables were generated based on data from men treated at the Johns Hopkins Hospital (JHH) from 1982 to 1991 [1] , during the pre-PSA era. However, with widespread use of PSA-based screening in the 1990s and early 2000s the population diagnosed with prostate cancer demonstrated a persistent trend toward earlier-stage, lowerrisk disease [8] . Indeed, over the last two decades, our institution has consistently observed a higher proportion of men treated with a PSA level of <4.0 ng/mL and clinical stage T1c disease, as well as a lower proportion presenting with PSA levels >10.0 ng/mL [9] [10] [11] . As such, the Partin Tables have been regularly updated to reflect the changing population [9, 10] , with the most recent update based on data from 2006 to 2011 [11] .
However, in recent years there have been substantial shifts in the approach to diagnosing and treating prostate cancer [12] . Suggesting the harms of PSA-based screening may outweigh its benefits, the United States Preventive Services Task Force (USPSTF) issued a Grade D recommendation to discourage PSA testing in men of all ages in 2012 [13] . Since then, there has been a significant decrease in the reported use of screening [14, 15] . Furthermore, emerging data from several institutions have supported the safety of active surveillance (AS) in selected men with favourable-risk disease [16] , and epidemiological data have shown more widespread adoption of AS [17, 18] . At the same time there has been a trend toward increasing use of RP as the treatment of choice for men with high-risk prostate cancer in the USA and abroad [19, 20] . These findings suggest a trend reversal in the population of men treated with RP in the last 5 yearstoward a higher, rather than lower, risk classification [21, 22] . Accordingly, we sought to update the Partin nomogram to better reflect the contemporary RP population.
Patients and Methods
From January 2010 to October 2015, 5278 men with localised prostate cancer underwent RP with pelvic lymph node dissection (PLND) at the JHH. Localised disease was defined as clinical stage T1c or T2 in accordance with the American Joint Committee on Cancer staging. All men were diagnosed based on prostate biopsy and assigned a Gleason score by expert genitourinary pathologists at our institution. There were 365 men who underwent neoadjuvant therapy or treatment with androgen or PSA-altering medications (e.g. 5a-reductase inhibitors) and were therefore excluded. An additional 454 subjects were excluded based on incomplete preoperative or pathological data, yielding a study cohort of 4459 men. This study was approved by the Institutional Review Board at the Johns Hopkins Medical Institutions.
Clinical and Pathological Data
Clinical stage was assigned based on examination by the attending surgeon. Consistent with clinical practice, the highest biopsy Gleason score was used for analysis in men with multiple positive cores of varying grade. After RP, the prostate and seminal vesicles were completely embedded and examined. The histological grade of the RP specimen was determined from the dominant nodule based on the 2005 International Society of Urological Pathology (ISUP) modified grading system [23] and reported according to the 2014 ISUP consensus guidelines using the new Grade Group (GG) system that originated at JHH [24] [25] [26] . While accuracy of the updated guidelines have been questioned with regard to classification of Gleason score 3 + 5 = 8 cancers as Grade Group 4 (GG4) [27] , this diagnosis was exceedingly rare in a large multi-institutional experience [25] and represented <1% of the present study population (n = 29).
The decision to perform PLND is provider-dependent at our institution, and PLND was performed in 89.9% of the study population. In general, PLND is performed unless the likelihood of LN involvement is <2%, in accordance with accepted guidelines [27] . Although similarly providerdependent, a standard PLND (including the area between the external iliac vein and obturator nerve plus the area below the obturator nerve onto the iliac vessels [28] ; termed an extended dissection by some) is pursued in most cases. All pelvic lymph nodes (LNs) were sectioned and examined for cancer. Overall pathological stage was classified as: organconfined (OC), if all cancer was confined to the prostate; extraprostatic extension (EPE), if cancer was evident outside the prostate and without involvement of seminal vesicles (SVs) or LNs; SV involvement (SV+), if cancer invaded the SVs in the absence of LN disease; and LN involvement (LN+), if prostate cancer was detected in the pelvic LNs. EPE was classified as established (i.e. non-focal) EPE or focal EPE, previously described as a few neoplastic glands outside the prostate in two or fewer slides [28] . Pathological stage was considered mutually exclusive such that SV+ patients, although by definition had EPE, only contributed to the SV+ category.
Statistical Analysis
Polychotomous logistic regression analysis was used to predict the probability of each pathological stage category: OC, EPE, SV+, or LN+ based on preoperative criteria. Preoperative variables included biopsy Gleason score (6, 3 + 4, 4 + 3/8, and 9-10), serum PSA level (0-4.0, 4.1-6.0, 6.1-10.0, and >10.0 ng/ mL), and clinical stage (T1c, T2a, and T2b/T2c). PSA level groups 0-2.5 and 2.6-4.0 ng/mL were combined due to a lack of significant difference in study outcomes between these groups [odds ratios (95% CI) for EPE, SV+, and LN+ were 0.8 (0.6-1.1), 0.6 (0.3-1.3), and 1.6 (0.6-4.4), respectively, for PSA level 2.6-4.0 ng/mL compared to ≤2.5 ng/mL]. Gleason scores 4 + 3 = 7 (GG3) and 8 (GG4) were similarly combined due to similar outcomes in these groups [odds ratios (95% CI) for EPE, SV+, and LN+ were 0.8 (0.6-1.2), 0.8 (0.5-1.4), and 0.8 (0.4-1.6), respectively, for Gleason score 8 compared to 4 + 3]. In the previous version of the Partin Tables we observed no difference between biopsy Gleason 4 + 3 and 8 in pathological stage outcomes [11] .
Bootstrap re-sampling with 1000 replications was performed to estimate 95% CIs for predicted probabilities of each pathological state. The area under the receiver operating characteristic curve (AUC) was used to measure discriminative ability of binary models representing each pathological stage compared to OC [29] . Similarly, calibration plots were used to graphically represent agreement between the predicted and actual probability of each pathological stage, based on the binary models. Statistical analysis was performed using SAS v9.4 (SAS Institute, Cary, NC, USA).
Results
Study cohort characteristics are given in Table 1 . The median (range) age at surgery was 60 (34-77) years and most patients (79%) were White. The median PSA level was 4.9 ng/mL, and 9% of men had a PSA level of >10.0 ng/mL. Nearly 80% of men had impalpable lesions at diagnosis (i.e. clinical stage T1c). Overall, 53% of the cohort had Gleason score ≥7 at biopsy, and 64% had Gleason score ≥7 in the RP specimen. On final surgical pathology, 74% of the treated population had OC disease.
The predicted probabilities of pathological outcomes based on specific classifications of clinical stage, PSA level, and biopsy Gleason score are listed in Table 2 . As shown in the table, among the clinical stage T1c population, the probability of OC cancer reached a peak of 92% in men with the most favourable preoperative features (PSA level 0-4.0 ng/mL and biopsy Gleason score 6), as compared to only 19% in those with a PSA level of >10.0 ng/mL and biopsy Gleason score 9-10 (GG5). In comparison, in men with clinical stage T2b or T2c disease, the corresponding probabilities of OC ranged from a high of 79% to a low of 5%.
As expected, a general trend toward advanced pathological stage was seen with increasing clinical stage, PSA level, and Gleason score. However, in some cases variation in these factors had a particularly strong impact on subsequent pathology. For example, the largest increase in probability of EPE was seen when biopsy Gleason score increased from 6 (GG1) to 3 + 4 (GG2), whereas changes from Gleason score 3 + 4 (GG2) to 4 + 3 (GG3) and higher resulted in smaller shifts in EPE risk. At the same time, predicted probabilities of SV+ and LN+ were fairly constant with increases in PSA up to 10.0 ng/ mL, but then rose sharply, more than doubling in men with PSA levels of >10.0 ng/mL compared to lower PSA levels. Notably, the probability of LN+ disease increased most substantially as Gleason score increased from the 4 + 3/8 (GG3-4) grouping to 9-10 (GG5), again doubling for most groups.
Based on binary logistic regression models, the AUCs for EPE, SV+, and LN+ relative to OC are listed in Table 3 . These values are consistent with our previous findings and suggest very good discrimination for SV+ and LN+. As previously observed, the modest discriminative ability of the model for EPE is probably explained by the fact that a substantial proportion of EPE was focal in nature (48%), with preoperative characteristics very similar to OC tumours, decreasing the model's ability to discriminate these two pathology outcomes. Indeed, a model comparing only nonfocal EPE with OC showed greater discriminative ability, AUC = 0.771, than a model of focal EPE vs OC, AUC = 0.673 (Table 3) . Nonetheless, associations with predictive variables were similar for focal and non-focal EPE, therefore these classifications remained combined in the final model. Calibration plots of predicted vs observed probabilities of each pathological outcome are shown in Fig. 1 . The in the contemporary population. After a consistent decline in the proportion of men treated with a PSA level of >10 ng/mL, from 25% in the initial cohort to 8% in our previous cohort, the present population was comprised of 9% of such men.
The proportion of treated men with biopsy Gleason score 6 (GG1) cancer has continued to decline, from 63% in the previous cohort to 47% in the present analysis. During the same period there has been a corresponding increase in highgrade disease: Gleason scores 8-10 (GG4-5) represent 10% of the contemporary cohort, the highest proportion of highgrade disease seen to date, and Gleason score 4 + 3 (GG3) has increased from 4% initially to 13% in the present cohort. Despite these departures from previous trends, the proportion of men with OC cancer has remained consistent since 2000 (73% in 2000-2005, 73% in 2006-2011, and 74% in 2010-2015). While the overall prevalence remained low, the proportion of men with SV+ and LN+ disease increased for the first time since the Partin Tables were introduced (from 3.4% to 4.1% for SV+ and 1.4% to 2.3% for LN+).
Discussion
While the merits of PSA-based screening are widely debated, there is strong evidence that trends in prostate cancer diagnosis and management have undergone a substantial shift in practice over recent years [12, 15] . Following the 2012 USPSTF recommendation, the prevalence of self-reported PSA testing in American men was 30.8% in 2013 -the lowest value since the question was first included in the National Health Interview Survey in 2005 [15] . At the same time, the use of AS for very-low-and low-risk cancers has increased significantly [17, 18] . These trends suggest that the population of men treated with RP may be rapidly evolving toward a higher-risk phenotype [12, 21, 22] , rendering predictive nomograms from previous eras inaccurate.
Considering this, we updated the Partin nomogram based on institutional data obtained from 2010 to present. Interestingly, 79% of the RP cohort had their cancers diagnosed based on elevated PSA levels (i.e. clinical stage T1c), essentially unchanged from 78% in the preceding era. On the other hand, only 47% of men who underwent RP were diagnosed with biopsy Gleason score 6 disease (GG1), a notable decline from 77% in 2000-2005 and 63% in 2006-2011. On final pathology, the proportion of men with OC cancer has remained stable since 2000, approximating three-quarters of the treated population. Subsequent data will be necessary to determine whether modest increases in SV+ (3.4% in the previous cohort to 4.1% in the present cohort) and LN+ (1.4% to 2.3%) disease suggest true shifts in stage among the highest-risk patients. Additionally, it should be acknowledged that data from our tertiary care referral centre may not be reflective of practice patterns observed in other settings.
The present analysis revealed several interesting trends. For one, despite its subjective nature and previous concerns of validity [30] , DRE remains a meaningful predictor of pathological stage, particularly classification with clinical stage T2b/c disease. For example, among the PSA level 0-4.0 ng/ mL population, the probabilities of OC disease for clinical stages T1c, T2a, and T2b/c, respectively, were 92%, 88%, and 79% for Gleason score 6 (GG1) disease; 77%, 70%, and 52% for Gleason score 3 + 4 (GG2) disease; 67%, 58%, and 37% for Gleason score 4 + 3 and 8 (GG3-4) disease; and 50%, 41%, and 21% for Gleason score 9-10 (GG5) disease. Indeed, the largest decrease in probability of OC pathology was seen when increasing clinical stage from T2a to T2b/c. As demonstrated in the present study (Table 2) , this trend persisted across PSA level and Gleason score groupings. Furthermore, these findings are consistent with National Comprehensive Cancer Network (NCCN) guidelines [31] , in which clinical stages T2b and T2c warrant no less than intermediate-risk classification, even in the presence of other low-risk findings.
The continued decrease in the proportion of our surgical cohort with low-grade cancers (Gleason score ≤6, i.e. GG1) is similarly noteworthy. The decline in Gleason score ≤6 cancers seen in the 2000-2005 cohort (77%) and 2006-2011 cohort (63%) was systematically explained by the 2005 ISUP Consensus Conference revisions, which initiated more frequent assignment of pattern 4 disease [23] . The observation that an even lower proportion (47%) of men was diagnosed with Gleason score ≤6 disease in the contemporary cohort could be explained by multiple factors. First, it is possible that the effect of grade migration brought about by the updated recommendations may have persisted into the contemporary era; definitive proof otherwise would require systematic re-analysis of the entire study cohort. At the same time, the decreasing proportion of treated men with lowgrade cancer may be explained in part by increasing use of AS at our institution over the past 5 years. Based on institutional reports, enrolment in AS increased from~50 men/year during January 1995 to March 2010 [32] to 125 men/year from April 2010 to our most recent analysis in June 2014 [33] . At the same time, the proportion of men undergoing immediate surgery for very-low-risk disease eligible for AS has decreased from 17% to 9%. These observations are consistent with reported national and regional trends in the use of AS [17, 18, 34] . Importantly, of 4283 men with biopsy core details available for the present analysis, only 541 men (12.6%) had very-low-risk cancer, five men (0.1%) were aged >75 years at surgery, and no men aged >75 years underwent RP for very low-risk disease. These findings suggest that a minimal proportion of our present data was composed of men traditionally classified as unnecessarily treated.
Interestingly, our present findings did not support the hypothesis that decreased screening would lead to a lower proportion of men diagnosed with impalpable, PSA-detected tumours. In fact, the proportions of men diagnosed with clinical stage T1c, T2a, T2b, and T2c disease have remained consistent since 2000. This is most probably explained by the observation that recent screening recommendations do not appear to have substantially affected the population referred to tertiary care centres to this point [35] . Notably, there was a small increase (8% vs 9%) in the proportion of men diagnosed with PSA levels of >10 ng/mL during the present era. This cohort represented the first time in which the proportion of men in the highest PSA category did not decline relative to the preceding era.
The observed trends in LN positivity continue to support existing guideline recommendations. The NCCN currently recommends performing PLND when the predicted probability of LN metastasis is ≥2% [31] , and European Association of Urology guidelines recommend use of the Briganti nomogram [36] . Considering a 2% threshold in the present analysis, as consistent with previous data [11] , PLND can be reasonably deferred in all Gleason score 6 (GG1) cases . ≥cT2a) . Similarly, all men with Gleason score ≥4 + 3 (GG≥3) cancer, regardless of other criteria, should undergo PLND. As Briganti et al. [36] set forth, an acceptable threshold for decision-making is one which avoids~50% of PLNDs at the cost of missing 12% of patients with LNpositive disease. Our recommendations above compare favourably to this, as these data indicate avoidance of 68% of biopsies while missing 10% of positive cases. Certainly these measures are subject to cohort risk-level and may be less favourable in other populations, and the total number of men in this analysis that were LN+ was limited. Nonetheless, our recommendations appear to be consistent with those of Briganti et al. [36] and the NCCN [31] .
The present study has potential limitations that should be discussed. As a large referral centre for RP, a substantial proportion of our treated population underwent diagnostic biopsy at an outside facility. While positive biopsy cores are routinely reviewed at our institution before treatment, the total number of cores obtained at biopsy was not available in 64.8% of the population. Thus, there may exist variation in ascertainment at biopsy that is not accounted for in these data. Of men with available data, however, only 3.4% had <12 cores obtained, and the observed concordance of biopsy and RP Gleason score was consistent with previous reports [37] , suggesting that the effect of this variation is limited. Similarly, 12-core biopsy became standard at our institution in 1997; therefore the extent of sampling may have led to more prevalent under grading in previous years. Nonetheless, these data are obtained from a single tertiary care centre and may not accurately reflect the general population. Also, the number of patients with Gleason score 8-10 cancers is relatively limited. As such, the findings of the present analysis should be further explored in high-risk populations, which may benefit from a unique predictive tool accounting specifically for variation among high-risk features. Finally, to ensure adequate statistical power, there was limited overlap (January 2010 to July 2011) with the cohort used in the previous Partin Tables analysis. Given several recent significant changes in prostate cancer policy and practice, however, we deemed it appropriate to contemporise the nomogram, and we think that the above limitations are more than counterbalanced by the significant strengths represented by our institution's multi-disciplinary expertise and wellestablished pathways for treatment of prostate cancer.
Despite the emergence of numerous sophisticated prognostic tools, the Partin Tables have remained relevant for over two decades since first being introduced. Meanwhile, the contemporary paradigm for RP has shifted toward a higherrisk population [12] . As such, traditional uses of the Partin Tables, such as identifying men curable with surgery, are being complemented by others more pertinent in a complex disease state, such as providing patients with clearly defined outcomes from which postoperative management decisions are derived. By providing a tangible framework for discussing surgical outcomes and related topics such as adjuvant radiotherapy, the Partin Tables have remained a standard element of pre-surgical counselling at our institution [38] . Given this practical role, and the wealth of information afforded by three inexpensive, readily-available clinical parameters, the Partin Tables are likely to remain useful well into the foreseeable future (the Partin Tables are available for clinical use via: http://urology.jhu.edu/prostate/).
